Clearside Biomedical, Inc.
CLSDDelisted Dec 8, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001539029
Clearside Biomedical, Inc. was delisted on Dec 8, 2025; its insiders filed their last Form 4 on Feb 24, 2025; 26 institutions reported holding it in 13F filings for Q3 2025, worth $2.18M in total; no superinvestor held it.
Q2 2024 vs. Q1 2024
How the institutions holding Clearside Biomedical, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 52 | 1 | 49 | −2 |
| Shares | 15.5M | 25.0K | 13.8M | −1.73M (−11.2%) |
| Value | $23.8M | $38.3K | $17.9M | −$5.82M (−24.5%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Clearside Biomedical, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Assenagon Asset Management S.A. | 283,193 | $368.2K | 0.00% |
| Squarepoint Ops LLC | 20,788 | $27.0K | 0.00% |
| Commonwealth Equity Services, LLC | 10,000 | $13.0K | 0.00% |
| Rockwood Wealth Management, LLC | 10,000 | $13.0K | 0.00% |
| Royal Bank of Canada | 568 | $1.00K | 0.00% |
| Russell Investments Group, Ltd. | 243 | $316 | 0.00% |
Sold out (8)
Institutions that held Clearside Biomedical, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Johnson & Johnson | 169,629 | $259.5K |
| Castleview Partners, LLC | 161,962 | $247.8K |
| Y-Intercept (Hong Kong) Ltd | 34,120 | $52.2K |
| SG Americas Securities, LLC | 32,270 | $49.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 25,408 | $38.9K |
| Cubist Systematic Strategies, LLC | 24,570 | $37.6K |
| UBS Group AG | 7,678 | $11.7K |
| Householder Group Estate & Retirement Specialist, LLC | 385 | $589 |
Not filed for Q2 2024 yet (1)
Institutions that held Clearside Biomedical, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 25,000 | $38.3K |